Restricted accessResearch articleFirst published online 2013-05
Short-Term Antiretroviral Therapy Fails to Reduce the Expanded Activated CCR5-Expressing CD4 + T Lymphocyte Population or to Restore the Depleted Naive Population in Chronically HIV-Infected Individuals with Active Pulmonary Tuberculosis
The effective role of antiretroviral (ARV) therapy in the regulation of CD4 T cell subset distribution, coreceptor expression, and activation status in individuals with chronic HIV also presenting with active pulmonary TB is not clearly understood. A cross-sectional analysis was performed on a total of 137 South African individuals. CCR5, CXCR4, and CD38 expression of CD4 T cell subsets in HIV-infected individuals with and without active pulmonary tuberculosis (TB) disease, pre- and post-ARV therapy, were determined by flow cytometry. In treatment-naive patients, CD4 T cells showed elevated surface expression of CCR5 and CD38 in TB/HIV coinfection as compared to HIV infection alone despite the overall percentage of CD4 T cells expressing CCR5 being reduced. Total CD38+ CD4 T cells were not significantly increased in either group; however, mean CD38 fluorescence was significantly higher in the context of TB infection. HIV/TB-coinfected individuals also displayed an increased percentage of activated (CD38+) CCR5+ CD4 T cells as compared to HIV patients alone. The naive CD4 T cell subset was depleted similarly in both HIV and HIV/TB groups. Only the HIV treatment group and not the TB-coinfected treatment group showed significantly decreased activated CCR5+ CD4 T cells, an increased percentage of naive T cells, and a decreased percentage of antigen-experienced T cells. This study highlighted an association of TB disease with immune activation, particularly of the CCR5+ CD4 T cell subset in HIV infection and the differential impact of ARV treatment. Further studies are needed to understand how TB coinfection confounds normal responses to ARV.
BassettIV, ChettyS, WangBet al.Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Aquir Immune Defic Syndr, 2012; 59,1:25–30.
3.
KampsBS, HoffmanC. Natural history of HIV. HIV Medicine. HoffmannC, RockstrohJK, KampsBS15th2007; 25. http://hivmedicine.com/textbook/cr.htm.
4.
AlmeidaAS, LagoPM, BoechatNet al.Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol, 2009; 183,1:718–731.
5.
VrisekoopN, MandiJN, GermainRN. Life and death as a T lymphocyte: From immune protection to HIV pathogenesis. J Biol, 2009; 8,10:91.
6.
Di MascioM, SeretiI, MatthewsLTet al.Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: Effects of highly active antiretroviral therapy provide insights into the mechanisms of naïve T-cell depletion. J Virol, 2006; 80,6:2665–2674.
7.
SodoraDL, SilvestriG. Immune activation and AIDS pathogenesis. AIDS, 2008; 22,4:439–446.
8.
DalgleishAG, BeverleyPC, ClaphamPR, GrawfordDH, GreavesMF, WeissRA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, 1984; 312,5996:763–767.
9.
PrincenK, ScholsD. HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokines Growth Factor Rev, 2005; 16,6:659–677.
10.
Rosas-TaracoAG, Arce-MendozaAY, Caballero-OlinG, Salinas-CarmonaMC. Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses, 2006; 22,1:45–51.
11.
MorrisL, CilliersT, BredellH, PhoswaM, MartinDJ. CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res and Hum Retroviruses, 2001; 17,8:697–701.
12.
JacobsGB, LoxtonAG, LatenA, RobsonB, van RensburgEJ, EngelbrechtS. Emergence and diversity of diversity of different HIV-1 subtypes in South Africa, 2000–2001. J Med Virol, 2009; 81,11:1852–1859.
13.
WiddringtonJ, PayneB, MedhiM, ValappilM, SchmidML. The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect, 2011; 62,1:87–92.
14.
LandayAl, BetterndorfD, ChanEet al.Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses, 2002; 18,2:95–102.
15.
HontelezJA, de VlasSJ, TauserFet al.The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PloS One, 2011; 6,7:e21919.
16.
BritoA, AlmeidaA, GonsalezCRet al.Successful HAART is associated with high β-chemokine levels in chronic HIV type 1-infected patients. AIDS Res Hum Retroviruses, 2007; 23,7:906–912.
17.
LangCG, LedermanMM, MaderoJSet al.Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr, 2002; 30,1:33–40.
18.
MarquesR, WilliamsA, EksmondUet al.Generalized immune activation as a direct result of activated CD4+ T cell killing. J Biol, 2009; 8,10:93.
19.
AiutiF, MezzaromaI. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART. AIDS Rev, 2006; 8,2:88–97.
20.
MassanellaM, NegredoE, Perez-AlvarezNet al.CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS, 2010; 24,7:959–968.
21.
BentwichZ, MaartensG, TortenD, LalAA, LalRB. Concurrent infections and HIV pathogenesis. AIDS, 2000; 14,14:2071–2081.
22.
MorrisL, DesmondJ M, BredellHet al.Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis in South Africa patients. J Infect Dis, 2003; 187,12:1967–1971.
23.
CorbeauP, ReynesJ. Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood, 2011; 117,21:5582–5590.
24.
MorenoS, HernandezB, DrondaF. Antiretroviral therapy in AIDS patients with tuberculosis. AIDS Rev, 2006; 8,3:115–124.
25.
BoyumA. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest, 1968; 21,Suppl 97:7.
26.
YaoJ, LiuZ, KoLS, PanG, JiangY. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods, 2005; 129,1:40–46.
27.
JuffermansNP, SpeelmanP, VerbonAet al.Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4 (+) T cells. Clin Infect Dis, 2001; 32,4:650–652.
28.
WoldayD, TegbaruB, KassuAet al.Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J Acquir Immune Defic Syndr, 2005; 39,3:265–271.
29.
ShalekoffS, PendleS, JohnsonD, MartinDJ, TiemessenCT. Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: Implications for pathogenesis. J Clin Immunol, 2001; 21,6:390–401.
30.
HannaLE, BoseJC, NayakK, SubramanyamS, SwaminathanS. Influence of active tuberculosis on chemokine and chemokine receptor expression in HIV-infected persons. AIDS Res Hum Retroviruses, 2005; 21,12:997–1002.
31.
MurphyK, TraversP, WalportM. T cell-mediated Immunity. Janeway's ImmunobiologyTaylor & Francis Group, LLC7th. Garland Science: New York, 2008; 323–377.
32.
AlmeidaAS, LagoPM, BoechatNet al.Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol, 2009; 183,1:718–731.
33.
GeldmacherC, NgwenyamaN, SchuetzAet al.Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med, 2010; 207,13:2869–2881.
34.
OstrowskiMA, JustementSJ, CatanzaroAet al.Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol, 1998; 161,6:3195–3201.
35.
DouekDC, BettsMR, LittleSJet al.Evidence of increased T cell turnover and decreased thymic output in HIV infection. J Immunol, 2001; 167,11:6663–6668.
36.
SmithKY, KumarS, PulvirentiJJ, GianesinM, KesslerHA, LandayA. CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART)J Acquir Immune Defic Syndr, 2002; 30,4:458–460.
37.
ZhangZN, ShangH, JiangYJet al.Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients. Chin Med J (Engl), 2006; 119,23:1966–1971.
38.
FunderburgN, KalinowskaM, EasonJet al.Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One, 2010; 5,10:e13188.
39.
BrizV, PovedaE, LopezE, Gonzalez MdelM, SovianoV, BenitoJM. Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. AIDS, 2008; 22,11:1371–1374.
40.
BenitoJM, LopezM, LozanoMet al.Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr, 2005; 38,4:373–381.
41.
MorhiH, PerelsonAS, TungKet al.Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med, 2001; 194,9:1277–1287.
42.
CassolE, MalfeldS, MashashaPet al.Persistent microbial translocation and immune activation in HIV-1 infected South Africans receiving combination antiretroviral therapy. J Infect Dis, 2010; 202,5:723–733.
43.
DandekarS. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep, 2007; 4,1:10–15.
44.
NakanjakoD, SsewanyanaI, Mayania-KizzaHet al.High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis, 2011; 11:43.
45.
AppayV, SauceD. Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol, 2008; 214,2:231–241.
46.
ChakrabartiLA. The paradox of simian immunodeficiency virus infection in sooty mangabeys: Active viral replication without disease progression. Front Biosci, 2004; 9:521–539.
47.
LoriF. Treating HIV/AIDS by reducing immune system activation: The paradox of immune deficiency and immune hyperactivation. Curr Opin HIV AIDS, 2008; 3,2:99–103.
48.
GuihotA, BourgaritA, CarcelainG, AutranB. Immune reconstitution after decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol, 2011; 32,3:131–137.
49.
AnthonyKB, YoderC, MetcallJAet al.Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr, 2003; 33,2:125–133.
50.
KhouryG, RajasuriarR, CameronPU, LewinSR. The role of naïve T-cells in HIV-1 pathogenesis: An emerging key player. Clin Immunol, 2011; 141,3:253–267.
